BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 3632912)

  • 21. [VM-26 and cytosine arabinoside in the treatment of acute refractory lymphoblastic leukemia in adults].
    Marín P; Grañena A; Carreras E; Sierra J; Olivé MT; Rozman C
    Sangre (Barc); 1984; 29(4-A):399-404. PubMed ID: 6594782
    [No Abstract]   [Full Text] [Related]  

  • 22. Teniposide (VM-26) in patients with non-squamous-cell carcinoma of the cervix. A phase II trial of the Gynecologic Oncology Group.
    Muss HB; Bundy BN; Given FT; Stehman FB
    Am J Clin Oncol; 1990 Apr; 13(2):117-8. PubMed ID: 2316480
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II study of VM-26 in adult malignancies.
    Spremulli E; Schulz JJ; Speckhart VJ; Wampler GL
    Cancer Treat Rep; 1980 Jan; 64(1):147-9. PubMed ID: 7379049
    [No Abstract]   [Full Text] [Related]  

  • 24. Teniposide in recurrent or advanced cervical carcinoma: a phase II trial in patients not previously treated with cytotoxic therapy.
    Pfeiffer P; Cold S; Bertelsen K; Panduro J; Sandberg E; Rose C
    Gynecol Oncol; 1990 May; 37(2):230-3. PubMed ID: 2344968
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Teniposide (VM-26) and cytosine arabinoside as consolidation therapy in adult high-risk patients with acute lymphoblastic leukemia.
    Hoelzer D; Thiel E; Löffler H; Büchner T; Ganser A; Heil G; Kurrle E; Heimpel H; Koch P; Lipp T
    Semin Oncol; 1987 Jun; 14(2 Suppl 1):92-7. PubMed ID: 3473688
    [No Abstract]   [Full Text] [Related]  

  • 26. Teniposide (VM-26) in patients with advanced refractory ovarian cancer: a phase II study of the Netherlands Joint Study Group for Ovarian Cancer.
    van der Burg ME; ten Bokkel Huinink WW; Vriesendorp R; van Oosterom AT; Neijt JP; Vermorken JB; van Putten WL; Kooiman A
    Eur J Cancer Clin Oncol; 1987 Jul; 23(7):997-8. PubMed ID: 3666002
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II study of teniposide in small cell carcinoma of the lung.
    Pedersen AG; Bork E; Osterlind K; Dombernowsky P; Hansen HH
    Cancer Treat Rep; 1984 Oct; 68(10):1289-91. PubMed ID: 6098366
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Results of a clinical study of an epipodophyllotoxin preparation (VM 26) in children with hemoblastoses].
    Kondrat'eva NA; Makhonova LA; Maiakova SA; Vialushkin BIa
    Probl Gematol Pereliv Krovi; 1981 Apr; 26(4):12-6. PubMed ID: 7015318
    [No Abstract]   [Full Text] [Related]  

  • 29. Phase II trial of teniposide in previously treated and untreated patients with advanced colorectal carcinoma: an Illinois Cancer Council Trial.
    Locker GY; Lanzotti V; Khandekar JD; Sweet D; Shaw J; Bitran J; Gordon L; Krauss S; Johnson C
    Cancer Treat Rep; 1986 Feb; 70(2):307-8. PubMed ID: 3948195
    [No Abstract]   [Full Text] [Related]  

  • 30. [Treatment of acute refractory lymphoblastic leukemia in the adult with VM-26 and ARA-C].
    Rafecas FJ; Sanz MA
    Sangre (Barc); 1984; 29(6):1052-3. PubMed ID: 6598235
    [No Abstract]   [Full Text] [Related]  

  • 31. Teniposide in the treatment of non-small cell lung carcinoma.
    Giaccone G; Donadio M; Ferrati P; Bonardi G; Ciuffreda L; Bagatella M; Calciati A
    Cancer Treat Rep; 1987 Jan; 71(1):83-5. PubMed ID: 3024829
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Teniposide (VM26) disposition in children with leukemia.
    Sinkule JA; Stewart CF; Crom WR; Melton ET; Dahl GV; Evans WE
    Cancer Res; 1984 Mar; 44(3):1235-7. PubMed ID: 6581866
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II evaluation of VM-26 in patients with metastatic transitional cell carcinoma of the urinary tract: an Eastern Cooperative Oncology Group study.
    Qazi R; Elson P; Khandekar JD
    Cancer Treat Rep; 1982 Feb; 66(2):405-6. PubMed ID: 7055823
    [No Abstract]   [Full Text] [Related]  

  • 34. VM-26 and cytarabine combination chemotherapy in refractory or relapsed adult acute lymphoblastic leukemia.
    Carella AM; Santini G; Martinengo M; Giordano D; Nati S; Congiu A; Risso M; Vimercati R; Cerri R; Rossi E
    Haematologica; 1984; 69(6):747-51. PubMed ID: 6441752
    [No Abstract]   [Full Text] [Related]  

  • 35. Phase II study of teniposide (VM26) in cutaneous T-cell lymphomas.
    Sorio R; Tirelli U; Zagonel V; Carbone A; Monfardini S
    Am J Clin Oncol; 1990 Feb; 13(1):14-6. PubMed ID: 2305716
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined VM-26 and cytosine arabinoside in treatment of refractory childhood lymphocytic leukemia.
    Rivera G; Aur RJ; Dahl GV; Pratt CB; Wood A; Avery TL
    Cancer; 1980 Mar; 45(6):1284-8. PubMed ID: 7357520
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I/pharmacokinetic study of intraperitoneal teniposide (VM 26).
    Canal P; Bugat R; Chatelut E; Pinel MC; Houin G; Plusquellec Y; Carton M
    Eur J Cancer Clin Oncol; 1989 May; 25(5):815-20. PubMed ID: 2737218
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Total-body irradiation and high-dose teniposide: a pilot study in bone marrow transplantation for patients with relapsed acute lymphoblastic leukemia.
    Krance RA; Forman SJ; Blume KG
    Cancer Treat Rep; 1987 Jun; 71(6):645-7. PubMed ID: 3555790
    [TBL] [Abstract][Full Text] [Related]  

  • 39. VM26: phase I and II studies.
    Macbeth FR
    Cancer Chemother Pharmacol; 1982; 7(2-3):87-91. PubMed ID: 7044595
    [No Abstract]   [Full Text] [Related]  

  • 40. Teniposide in squamous cell carcinoma of the cervix: a phase II trial of the Gynecologic Oncology Group.
    Muss HB; Bundy BN; Yazigi R; Yordan E
    Cancer Treat Rep; 1987 Sep; 71(9):873-4. PubMed ID: 3621222
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.